Quantum Leap Healthcare Collaborative
The I-SPY Trials
For Patients
ABOUT
I-SPY 2 Trial
Resources
Funding & Support
Agents & Results
I-SPY Agents
Manuscripts
Meeting Abstracts
Collaborate
Proposal Submissions
Partner With Us
News
Latest News
Feature Articles
I-SPY in the News
Media Center
People
Leadership
Clinical Sites
Contact Us
FOR PATIENTS
News
I-SPY in the News
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
Close
I-SPY Email List Sign-up
First Name:
Last Name:
Email Address:
Breast cancer patient/family/friend
Research/Medical Professional
Just Interested
Thank you, your subscription is activated.
If you change your mind, you can
unsubscribe
at any time.
Oops! Something went wrong while submitting the form.
Highlights
I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies
Cancer Cell
June 14, 2022
Esserman brings urgency for ‘learning healthcare’ to learn faster, better
BioCentury
June 6, 2022
Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting
Natera, Inc.
April 11, 2022
Recent Coverage
December 13, 2013
-
Wall St Journal
Two Experimental Breast-Cancer Drugs Pass Major Milestone in Study
October 2, 2010
-
Wall St Journal
A new Rx for medicine
May 1, 2010
-
Nature Biotechnology
Biomarker-led adaptive trial blazes a trail in breast cancer
Previous
Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.
Sign Up
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.